HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bo Huang Selected Research

utomilumab

1/2020First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.
12/2019A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
1/2018Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
9/2017Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bo Huang Research Topics

Disease

174Neoplasms (Cancer)
06/2022 - 08/2002
33Inflammation (Inflammations)
11/2022 - 11/2008
23Neoplasm Metastasis (Metastasis)
01/2022 - 07/2007
16Infections
12/2022 - 05/2007
14Breast Neoplasms (Breast Cancer)
01/2022 - 02/2011
14Nasopharyngeal Carcinoma
01/2021 - 03/2005
13Carcinogenesis
07/2022 - 05/2007
11Fibrosis (Cirrhosis)
03/2022 - 12/2013
11Wounds and Injuries (Trauma)
02/2022 - 06/2012
11Melanoma (Melanoma, Malignant)
11/2019 - 08/2008
10COVID-19
07/2022 - 01/2020
9Insulin Resistance
11/2021 - 04/2011
8Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 07/2010
8Intervertebral Disc Degeneration
01/2021 - 12/2011
8BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2021 - 01/2008
8Lung Neoplasms (Lung Cancer)
12/2020 - 01/2012
7Stomach Neoplasms (Stomach Cancer)
07/2022 - 06/2013
7Disease Progression
07/2022 - 07/2010
7Adenocarcinoma of Lung
02/2022 - 01/2015
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2022 - 01/2011
7Hypoxia (Hypoxemia)
10/2021 - 02/2014
7Sepsis (Septicemia)
01/2021 - 02/2013
7Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
01/2021 - 07/2013
7Malaria
01/2021 - 07/2013
7Hypertrophy
07/2019 - 02/2013
7Hepatocellular Carcinoma (Hepatoma)
01/2019 - 01/2003
6Atrophy
11/2021 - 01/2009
6Fatigue
05/2021 - 02/2015
6Carcinoma (Carcinomatosis)
12/2020 - 08/2002
6Body Weight (Weight, Body)
01/2019 - 02/2015
5Hemorrhage
02/2022 - 01/2017
5Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 02/2011
5Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar)
12/2020 - 11/2012
5Pain (Aches)
04/2020 - 10/2013
5Pathologic Processes
01/2020 - 01/2011
4Triple Negative Breast Neoplasms
12/2022 - 01/2017
4Hyperoxia
11/2022 - 10/2008
4IGA Glomerulonephritis (IGA Nephropathy)
10/2022 - 02/2018
4Fever (Fevers)
07/2022 - 01/2020
4Neurodegenerative Diseases (Neurodegenerative Disease)
01/2022 - 11/2012
4Parkinson Disease (Parkinson's Disease)
01/2022 - 06/2015
4Liver Neoplasms (Liver Cancer)
03/2021 - 12/2010
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 01/2017
4Pneumonia (Pneumonitis)
01/2021 - 01/2016
4Leukemia
01/2020 - 01/2002

Drug/Important Bio-Agent (IBA)

66Proteins (Proteins, Gene)FDA Link
09/2022 - 06/2005
24MicroRNAs (MicroRNA)IBA
11/2022 - 01/2010
21Biomarkers (Surrogate Marker)IBA
11/2022 - 06/2011
20Biological ProductsIBA
01/2022 - 10/2009
18Pharmaceutical PreparationsIBA
11/2022 - 01/2012
16Messenger RNA (mRNA)IBA
11/2022 - 10/2008
14Peptides (Polypeptides)IBA
01/2021 - 01/2002
14AntigensIBA
11/2019 - 01/2002
11Glucose (Dextrose)FDA LinkGeneric
01/2022 - 09/2011
11Small Interfering RNA (siRNA)IBA
12/2018 - 06/2005
10LigandsIBA
04/2021 - 02/2008
9VaccinesIBA
03/2022 - 02/2015
9RNA (Ribonucleic Acid)IBA
01/2022 - 05/2010
9Therapeutic UsesIBA
07/2019 - 09/2003
9DNA (Deoxyribonucleic Acid)IBA
01/2019 - 05/2010
8Interleukin-2 (IL2)IBA
01/2022 - 06/2008
8Interleukin-6 (Interleukin 6)IBA
10/2021 - 06/2005
8CytokinesIBA
12/2020 - 09/2010
7Long Noncoding RNAIBA
03/2022 - 01/2017
7NF-kappa B (NF-kB)IBA
01/2021 - 05/2007
6avelumabIBA
06/2022 - 01/2019
6Cisplatin (Platino)FDA LinkGeneric
01/2022 - 09/2010
6Biocompatible Materials (Biomaterials)IBA
01/2022 - 01/2017
6EnzymesIBA
10/2021 - 06/2012
6LipopolysaccharidesIBA
04/2021 - 06/2005
6CollagenIBA
01/2021 - 12/2011
6AntioxidantsIBA
10/2019 - 10/2008
6Insulin (Novolin)FDA Link
12/2018 - 09/2011
5Transcription Factors (Transcription Factor)IBA
10/2021 - 05/2006
5Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
01/2021 - 01/2018
5Imatinib Mesylate (Gleevec)FDA Link
01/2021 - 04/2012
5CholesterolIBA
01/2021 - 04/2011
5Fibronectins (Fibronectin)IBA
01/2020 - 09/2003
5Reactive Oxygen Species (Oxygen Radicals)IBA
01/2020 - 01/2015
5Atrial Natriuretic Factor (ANF)IBA
01/2019 - 05/2015
5DNA-Binding Proteins (DNA Binding Protein)IBA
01/2018 - 03/2013
5Estrogen ReceptorsIBA
01/2018 - 02/2011
5FibrinIBA
01/2018 - 07/2012
5Interleukin-17 (Interleukin 17)IBA
12/2013 - 08/2008
4CreatinineIBA
10/2022 - 07/2018
4Antiviral Agents (Antivirals)IBA
07/2022 - 05/2016
4CateninsIBA
01/2022 - 01/2017
4Circular RNAIBA
01/2022 - 09/2021
4Sunitinib (Sutent)FDA Link
01/2022 - 02/2011
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2021 - 11/2016
4InflammasomesIBA
01/2021 - 02/2013
4RNA-Binding Proteins (RNA-Binding Protein)IBA
12/2020 - 01/2010
4AntibodiesIBA
10/2020 - 11/2012
4Immunoglobulin G (IgG)IBA
10/2020 - 09/2017
4utomilumabIBA
01/2020 - 09/2017

Therapy/Procedure

53Therapeutics
01/2022 - 06/2005
20Drug Therapy (Chemotherapy)
06/2022 - 01/2003
14Immunotherapy
06/2022 - 03/2007
9Radiotherapy
01/2021 - 02/2011
4Oral Administration
01/2021 - 06/2007